|
業務類別
|
Biotechnology |
|
業務概覽
|
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |
| 公司地址
| 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608 |
| 電話號碼
| +1 510 505-2680 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.4dmoleculartherapeutics.com |
| 員工數量
| 227 |
| Mr. Noriyuki Kasahara, M.D.,PhD |
Chief Scientific Officer |
-- |
29/04/2025 |
| Mr. Scott Bizily, J.D.,PhD |
Chief Legal and Corporate Secretary |
-- |
29/04/2025 |
| Dr. Fariborz Kamal, PhD |
Chief Operating Officer |
美元 546.27K |
07/01/2026 |
| Mr. Robert Young Kim, M.D. |
Chief Medical Officer |
-- |
29/04/2025 |
| Ms. Theresa Janke |
Chief of Staff |
-- |
12/04/2023 |
| Mr. David Kirn, M.D. |
Director, President and Chief Executive Officer |
美元 662.78K |
07/01/2026 |
| Mr. Kristian F. Humer |
Chief Financial Officer |
-- |
17/11/2025 |
|
|
| Ms. Susannah Gray, M.B.A. |
Independent Director |
29/04/2025 |
| Dr. Charles P. Theuer, M.D.,PhD |
Independent Director |
29/04/2025 |
| Dr. John F. Milligan, PhD |
Executive Chairman of the Board |
29/04/2025 |
| Mr. Glenn P. Sblendorio |
Director |
07/01/2026 |
| Ms. Nancy Miller-Rich |
Independent Director |
29/04/2025 |
| Mr. Jacob M. Chacko, M.B.A.,M.D. |
Independent Director |
29/04/2025 |
| Mr. David Kirn, M.D. |
Director, President and Chief Executive Officer |
07/01/2026 |
| Ms. Shawn Cline Tomasello, M.B.A. |
Independent Director |
29/04/2025 |
|
|
|
|
